Fibrodysplasia Ossificans Progressiva (FOP) Clinical Trial
Official title:
FOP Connection: A Global Registry for the Fibrodysplasia Ossificans Progressiva Community
The Fibrodysplasia Ossificans Progressiva (FOP) Connection Registry is a global, non-interventional, voluntary database that captures demographic and disease data directly from FOP patients and their caregivers via a secure, web-based patient portal. A physician portal (in development) will allow physicians to enter clinical data about their patients. The objectives are to organize the international FOP community for participation in clinical trials; to enable FOP patients worldwide to report data in a shared forum; to improve the collective understanding of FOP natural history; and to advance the understanding of FOP treatment outcomes.
| Status | Recruiting |
| Enrollment | 800 |
| Est. completion date | December 2025 |
| Est. primary completion date | July 2025 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | N/A and older |
| Eligibility |
Inclusion Criteria: - Participants must have a confirmed diagnosis of FOP. - Participants (or a parent or legal guardian) must be willing and able to provide written informed consent. Exclusion Criteria: - There are no exclusion criteria. |
| Country | Name | City | State |
|---|---|---|---|
| United States | The International FOP Association | Casselberry | Florida |
| Lead Sponsor | Collaborator |
|---|---|
| The International FOP Association |
United States,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Other | Patient Reported Changes in Activities of Daily Living Using the FOP-Physical Functioning Questionnaire (PFQ) | Baseline, then every six months for up to 10 years | ||
| Other | Patient Reported Changes in Overall Health Using the PROMIS Global Health Scale | Baseline, then every six months for up to 10 years | ||
| Other | Patient Reported Changes in the Need for Assistive Devices, Aids, Attendants, and Adaptations Using a Survey Developed by the IFOPA | The patient is able to respond Yes or No to questions related to his/her need for Assistive Devices, Aids, Attendants, and Adaptations as a result of his/her FOP disease. | Baseline, then every six months for up to 10 years | |
| Primary | Patient Reported Changes in New Bone Growth Using a Patient-Directed Survey Developed by the IFOPA | The patient is able to report changes in new bone growth among 27 joints and body locations. | Baseline, then every six months for up to 10 years | |
| Primary | Patient Reported Changes in Episodic Flare-Ups Using a Patient-Directed Survey Developed by the IFOPA | The patient is able to report changes in episodic flare-ups among 27 joints and body locations. | Baseline, then every six months for up to 10 years | |
| Primary | Patient Reported Changes in Mobility Using a Patient-Directed Survey Developed by the IFOPA | The patient is able to report changes in mobility among 27 joints and body locations. | Baseline, then every six months for up to 10 years | |
| Secondary | Patient Reported Changes in Health Resource Utilization Using a Patient-Directed Survey Developed by the IFOPA | The number of visits to a Physician and a Dentist, as well as the number of hospitalizations and reasons for the hospitalizations, are used to assess health resource utilization. | Baseline, then every six months for up to 10 years | |
| Secondary | Patient Reported Changes in Signs Related to the Ear Using a Patient-Directed Survey Developed by the IFOPA | The patient is able to report new or continuing health issues related to the ears. | Baseline, then every six months for up to 10 years | |
| Secondary | Patient Reported Changes in Signs Related to the Skin Using a Patient-Directed Survey Developed by the IFOPA | The patient is able to report new or continuing health issues related to the skin. | Baseline, then every six months for up to 10 years | |
| Secondary | Patient Reported Changes in Signs Related to the Central Nervous System Using a Patient-Directed Survey Developed by the IFOPA | The patient is able to report new or continuing health issues related to the central nervous system. | Baseline, then every six months for up to 10 years | |
| Secondary | Patient Reported Changes in Signs Related to the Pulmonary System Using a Patient-Directed Survey Developed by the IFOPA | The patient is able to report new or continuing health issues related to the pulmonary system. | Baseline, then every six months for up to 10 years | |
| Secondary | Patient Reported Changes in Signs Related to the Gastrointestinal System Using a Patient-Directed Survey Developed by the IFOPA | The patient is able to report new or continuing health issues related to the gastrointestinal system. | Baseline, then every six months for up to 10 years | |
| Secondary | Patient Reported Changes in Signs Related to the Cardiovascular System Using a Patient-Directed Survey Developed by the IFOPA | The patient is able to report new or continuing health issues related to the cardiovascular system. | Baseline, then every six months for up to 10 years | |
| Secondary | Patient Reported Changes in Signs Related to the Renal System Using a Patient-Directed Survey Developed by the IFOPA | The patient is able to report new or continuing health issues related to the renal system. | Baseline, then every six months for up to 10 years | |
| Secondary | Patient Reported Changes in Signs Related to the Endocrine System Using a Patient-Directed Survey Developed by the IFOPA | The patient is able to report new or continuing health issues related to the endocrine system. | Baseline, then every six months for up to 10 years |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05090891 -
To Assess the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans Progressiva
|
Phase 2 | |
| Active, not recruiting |
NCT05027802 -
A Rollover Study to Further Evaluate the Safety and Efficacy of Palovarotene Capsules in Male and Female Participants Aged ≥14 Years With Fibrodysplasia Ossificans Progressiva (FOP) Who Have Completed the Relevant Parent Studies.
|
Phase 3 | |
| Completed |
NCT06064656 -
A Non-Interventional Study of Clinical Characteristics and Mortality of US Patients With Fibrodysplasia Ossificans Progressiva (FOP)
|